X4 Pharmaceuticals (XFOR) Depreciation & Amortization (CF) (2017 - 2025)
X4 Pharmaceuticals (XFOR) posted Depreciation & Amortization (CF) of $223000.0 for Q4 2025, little changed on a QoQ basis from $223000.0 in Q3 2025, and down 18.32% year-over-year from $273000.0 in Q4 2024.
X4 Pharmaceuticals (XFOR) Depreciation & Amortization (CF) (2017 - 2025) Analysis & Trends
X4 Pharmaceuticals' Depreciation & Amortization (CF) history runs 9 years deep, the most recent figure standing at $223000.0 for Q4 2025.
- Quarterly Depreciation & Amortization (CF) fell 18.32% year-over-year to $223000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.3 million (up 60.43% YoY) and the FY2025 annual result came in at $1.3 million, up 60.43% from the prior year.
- Depreciation & Amortization (CF) was $223000.0 for Q4 2025 at X4 Pharmaceuticals, roughly flat from $223000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $476000.0 in Q1 2025 and bottomed at $62000.0 in Q4 2023.
- A 5-year average of $175200.0 and a median of $132000.0 in 2021 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2024 — Depreciation & Amortization (CF) tumbled 51.18% — and 2025, when it surged 667.74%.
- X4 Pharmaceuticals' Depreciation & Amortization (CF) stood at $132000.0 in 2021, then retreated by 6.06% to $124000.0 in 2022, then plunged by 50.0% to $62000.0 in 2023, then surged by 340.32% to $273000.0 in 2024, then fell by 18.32% to $223000.0 in 2025.
- Business Quant data shows XFOR's Depreciation & Amortization (CF) at $223000.0 in Q4 2025, $223000.0 in Q3 2025, and $355000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 41.14 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 2.20 Mn |
| 10 | X4 Pharmaceuticals | 167.90 Mn | -49.15 Mn | 2.20 Mn | 223,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 223,000.00 |
| Dec 31, 2025 | 223,000.00 |
| Sep 30, 2025 | 223,000.00 |
| Sep 30, 2025 | 223,000.00 |
| Jun 30, 2025 | 355,000.00 |
| Jun 30, 2025 | 355,000.00 |
| Mar 31, 2025 | 476,000.00 |
| Mar 31, 2025 | 476,000.00 |
| Dec 31, 2024 | 273,000.00 |
| Dec 31, 2024 | 273,000.00 |
| Sep 30, 2024 | 267,000.00 |
| Sep 30, 2024 | 267,000.00 |
| Jun 30, 2024 | 194,000.00 |
| Jun 30, 2024 | 194,000.00 |
| Mar 31, 2024 | 62,000.00 |
| Mar 31, 2024 | 62,000.00 |
| Dec 31, 2023 | 62,000.00 |
| Dec 31, 2023 | 62,000.00 |
| Sep 30, 2023 | 104,000.00 |
| Sep 30, 2023 | 104,000.00 |